Organogenesis Holdings Inc. (ORGO)
US — Healthcare Sector
Automate Your Wheel Strategy on ORGO
With Tiblio's Option Bot, you can configure your own wheel strategy including ORGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORGO
- Rev/Share 3.6324
- Book/Share 2.9143
- PB 1.5442
- Debt/Equity 0.1755
- CurrentRatio 4.1222
- ROIC -0.0451
- MktCap 376756380.0
- FreeCF/Share -0.0554
- PFCF -53.8147
- PE -20.1341
- Debt/Assets 0.0912
- DivYield 0
- ROE -0.0637
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
ORGO
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby.
Read More
About Organogenesis Holdings Inc. (ORGO)
- IPO Date 2017-01-05
- Website https://organogenesis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Gary S. Gillheeney Sr.
- Employees 869
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.